Carl Zeiss Meditec AG Financial Results 9M 2021/22 | Performance & Future Growth with CEO and CFO

Carl Zeiss Meditec AG 9M 2021/22: Key Takeaways Company Performance Overview In an update to investors, Carl Zeiss Meditec AG revealed its financial achievements and strategic advances for the first nine months of the fiscal year 2021/22. Under the leadership of CEO Dr Markus Weber and the CFO, the company showcased a notable revenue growth of 11.2% year-over-year, reaching €1,332.9 million, alongside a remarkable 36.0% surge in order intake. Despite the global supply chain challenges and the pandemic’s impact, particularly evident in the lockdowns in Shanghai, Carl Zeiss Meditec has not only navigated these hurdles with resilience but also capitalised on strategic opportunities across its Ophthalmic Devices and Microsurgery units, leading to disproportionate growth in orders compared to revenue. The company has demonstrated a diversified strength with contributions from all strategic business units and regions. In the Ophthalmic Devices sector, an 11.2% growth was recorded, significantly fueled by recurring revenue streams. Similarly, the Microsurgery segment witnessed an 11.2% increase in revenue. Geographically, the EMEA, Americas, and APAC regions all reported upward trends, with notable performances in core European markets, the United States, South America, China, and India. Financially, the EBIT margin slightly declined to 20.7% due to planned high investments in Sales & Marketing and R&D, despite a close-to-previous-year operating result of €275.9 million. The detailed presentation underscored Carl Zeiss Meditec’s strategic focus on increasing recurring revenue streams and investing to ensure sustained growth above a 20% EBIT margin in the medium term. As Carl Zeiss Meditec AG continues to navigate the complexities of the global market with a strong financial foundation and strategic foresight, investors are given a clear vision of the company’s robust health and ambitious growth trajectory for the remainder of the fiscal year and beyond. Strategic Business Unit and Regional PerformanceFinancial HighlightsInvestor Outlook ================================= ▶️ Other videos:Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ ================================= T&C This publication is for informational purposes only and does not constitute investment advice. By using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.